Global Patent Index - EP 0663958 A4

EP 0663958 A4 19991020 - INHIBITION OF CYST FORMATION BY CYTOSKELETAL SPECIFIC DRUGS.

Title (en)

INHIBITION OF CYST FORMATION BY CYTOSKELETAL SPECIFIC DRUGS.

Title (de)

HEMMUNG DER BILDUNG VON ZYSTEN MITTELS ZYTOSKLETTSPEZIFISCHER ARZNEIMITTEL.

Title (fr)

INHIBITION DE LA FORMATION DE KYSTES A l'AIDE DE MEDICAMENTS SPECIFIQUES CYTOSQUELETTIQUES.

Publication

EP 0663958 A4 19991020 (EN)

Application

EP 93922390 A 19930924

Priority

  • US 9309124 W 19930924
  • US 95127092 A 19920925

Abstract (en)

[origin: WO9408041A1] The invention provides a method of treating a mammal having a cystic disease. This method includes identifying a mammal having a cystic disease, and administering to the identified mammal a pharmacologically effective anti-cystic amount of an agent that interferes with the normal functioning of a cytoskeletal component or one that inhibits delivery of membrane proteins to the membrane. The agent is administered in a pharmacologically acceptable carrier, excipient or diluent. The invention also includes an (in vitro) assay system and use of such a system to identify agents useful in the treatment of cystic diseases.

IPC 1-7

C12Q 1/02

IPC 8 full level

A61K 31/165 (2006.01); A61K 31/335 (2006.01); A61K 31/34 (2006.01); A61K 31/365 (2006.01); A61K 31/40 (2006.01); A61K 31/415 (2006.01); A61K 31/475 (2006.01); A61K 38/08 (2019.01); C12N 5/071 (2010.01); G01N 33/50 (2006.01)

CPC (source: EP US)

A61K 31/165 (2013.01 - EP); A61K 31/335 (2013.01 - EP); A61K 31/34 (2013.01 - EP); A61K 31/365 (2013.01 - EP); A61K 31/40 (2013.01 - EP); A61K 31/415 (2013.01 - EP); A61K 31/475 (2013.01 - EP); A61K 38/08 (2013.01 - EP US); C12N 5/0686 (2013.01 - EP); G01N 33/5008 (2013.01 - EP); C12N 2503/02 (2013.01 - EP); G01N 2500/00 (2013.01 - EP)

Citation (search report)

  • [XY] S. RUBINO ET AL.: "The cytoskeleton of hydatid cyst cultured cells and its sensitivity to inhibitors", EUR. J. CELL. BIOL, vol. 30, no. 2, 1983, pages 182 - 190, XP000616612
  • [X] WOO, D.D.-L.: "Cytoskeletal specific drugs inhibit in-vitro cyst formation.", J. AM. SOC. NEPHROL., vol. 3, no. 3, September 1992 (1992-09-01), pages 304, XP002025249
  • [X] Y. RAVIA: "Differences between cystic fibrosis and normal cells in the degree of satellite association", HUM. GENET., vol. 71, no. 4, December 1985 (1985-12-01), pages 294 - 300, XP000616611
  • [X] G.L. FORREST: "Colchicine Binding activity and Tyrosyl tubulin ligase activity in normal and cystic fibrosis fibroblasts.", BIOCHEM. BIOPHYS. RES. COMM., vol. 98, no. 1, 15 January 1981 (1981-01-15), pages 324 - 329, XP000616636
  • [XP] B. SIEGAL: "The polycystic kidney donor", TRANSPLANTATION, vol. 54, no. 6, December 1992 (1992-12-01), pages 1131, XP000616618
  • [Y] BUDAVARI, S. ED.: "The Merck Index", 1989, MERCK & CO., INC., RAHWAY, N.Y., U.S.A., XP002025339
  • [A] R. MANGOO-KARIM ET AL.: "RENAL EPITHELIAL CYST FORMATION AND ENLARGEMENT IN VITRO: DEPENDENCE ON cAMP.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, August 1989 (1989-08-01), WASHINGTON US, pages 6007 - 6011, XP002109991
  • See references of WO 9408041A1

Designated contracting state (EPC)

DE ES FR GB IT

DOCDB simple family (publication)

WO 9408041 A1 19940414; AU 5140193 A 19940426; CA 2145680 A1 19940414; EP 0663958 A1 19950726; EP 0663958 A4 19991020

DOCDB simple family (application)

US 9309124 W 19930924; AU 5140193 A 19930924; CA 2145680 A 19930924; EP 93922390 A 19930924